Lab Work for Immuno Disorders: 25.0% of denials overturned
In 16 California IMR decisions from 2015 to 2025, reviewers overturned 4 (25.0%). In the last five years: 25.0% of 4. 3 were medical-necessity disputes, 13 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 1 | 0.0% |
| 2024 | 1 | 0.0% |
| 2025 | 2 | 50.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 7 | 14.3% | 25.0% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 3 | 33.3% | 25.0% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 3 | 0.0% | 25.0% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for routine blood monitoring (including dihydrotestosterone (DHT) and estradiol levels) for side effects of finasteride. This patient has a diagnosis of androgenetic alopecia. Finasteride is U.S. Food and Drug Administration (FDA)-approved for this patient’s condition. Finasteride functions as an inhibitor of 5-alpha reductase …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for gene testing. Findings: The three physician reviewers found this patient was suspected to have Muir-Torre syndrome based on her skin biopsy and family history. Muir-Torre syndrome is a rare autosomal dominant condition characterized by the association of at least one sebaceous skin tumor and at least one visceral malignancy. …”
“Nature of Statutory Criteria/Case Summary: The parent of a 17-year-old enrollee has requested authorization and coverage for whole exome sequencing (WES) for evaluation of the enrollee’s common variable immune deficiency, granulomatous lymphcytic interstitial lung disease (GLIID), and oxalate distal neuropathy. Findings: 2/3 of the physician reviewers found that WES is a technology whereby the portion of the genome consisting of …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for an adalimumab blood test. A study found that serum drug levels and the presence of anti-drug antibodies did not predict disease activity in patients with axial spondyloarthritis or rheumatoid arthritis. This study did not support the use of blood testing to determine serum medication levels and anti-drug antibody testing …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Lab Work denials for Immuno Disorders overturned?
In 16 California IMR decisions from 2015 to 2025, reviewers overturned 4 (25.0%). In the last five years: 25.0% of 4. 3 were medical-necessity disputes, 13 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.